Physician profile
Karen Chu
NPI 1053436899
$3,963.73
in general payments reported to CMS, 2019-2025
29 companies · $308 in 2025
The $308 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $654 · 2020: $744 · 2021: $805 · 2022: $669 · 2023: $515 · 2024: $269 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $998 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $997.61 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $832.94 | 2019-2023 | Prolia, Evenity |
| Abbvie INC. | $621.51 | 2019-2022 | |
| Ethicon US, LLC | $338.64 | 2019-2024 | Harmonic, Stratafix, Dermabond |
| Therapeuticsmd, INC. | $306.38 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $241.78 | 2019-2025 | |
| Avion Pharmaceuticals | $227.82 | 2019-2021 | |
| Astellas Pharma US INC | $219.59 | 2023-2025 | Veozah |
| Myovant Sciences INC. | $176.92 | 2021-2022 | |
| Applied Medical Resources Corporation | $145.13 | 2021 | |
| Mayne Pharma Commercial LLC | $126.36 | 2022-2024 | |
| Coopersurgical, INC. | $88.76 | 2020-2025 | Paragard T 380a |
| Mylan Pharmaceuticals INC. | $83.28 | 2020-2021 | |
| Biogen, INC. | $75.26 | 2024-2025 | Zurzuvae |
| Shield Therapeutics INC | $61.25 | 2023-2025 | Accrufer |
| Millicent US INC | $54.93 | 2024-2025 | Femring, Intrarosa, Femlyv |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $47.19 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $37.30 | 2019-2021 | |
| Organon LLC | $35.21 | 2021-2024 | |
| Medicem INC. | $28.95 | 2023 | |
| Vertex Pharmaceuticals Incorporated | $26.72 | 2025 | |
| Ascend Therapeutics US, LLC | $25.00 | 2023 | |
| Hologic Sales and Service, LLC | $23.43 | 2022 | |
| Exact Sciences Corporation | $23.10 | 2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $22.74 | 2023 | Myfembree |
| Agile Therapeutics, INC. | $21.94 | 2022 | |
| Exeltis, USA INC. | $20.00 | 2019 | |
| Octapharma USA, INC. | $19.99 | 2025 | Fibryga |
| Minerva Surgical, INC | $18.71 | 2024 | |
| Meditrina | $12.90 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.